SCHEMBL26917652

SCHEMBL26917652

O=C1CCN(Cc2ccccc2)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.62
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
KCNH2 Q12809 1/20 0.41
MDH2 P40926 1/20 0.41
KMT2A Q03164 2/20 0.41
MDM2 Q00987 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
POLB P06746 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
SRPK1 Q96SB4 1/20 0.41
CLPP Q16740 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4692742 0.90 ATM (0.59) ATMDDB1CRBNL3MBTL1DRD2
SCHEMBL22719691 0.84 CHRM5 (0.54) ATML3MBTL1DRD2KDM4EALDH1A1
SCHEMBL29505057 0.84 CHRM5 (0.54) ATML3MBTL1DRD2KDM4EALDH1A1
SCHEMBL426981 0.79 KMT2A (0.54) DDB1CRBNL3MBTL1KMT2AMDM2
SCHEMBL8490913 0.79 ACHE (0.48) ATMDRD2DRD3KCNH2KDM4E
SCHEMBL28041701 0.78 NOTUM (0.48) ATMKMT2AALDH1A1GAASRPK1
SCHEMBL26915821 0.76 MAPT (0.49) ATML3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL2048285 0.74 HDAC1 (0.52) ATMDRD2DRD3KCNH2KMT2A
SCHEMBL29630864 0.74 HDAC1 (0.52) ATMDRD2DRD3KCNH2KMT2A
SCHEMBL6819309 0.73 LMNA (0.57) ATMDRD2DRD3KCNH2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158412-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF FAXIAN THERAPEUTICS, LLC 2024-05-16 US disclosed
EP-4288442-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF Faxian Therapeutics, LLC (US) 2023-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158412-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF USP7, USP28, USP1 ATM 1971/4885DDB1 334/4885CRBN 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.